ROTH Capital Partners Acts as Sole Placement Agent
for Neovacs (Euronext Growth Paris: ALNEV)
in its €6.0 Million PIPE

For more information please contact:

Investment Banking
Eric B. Cheng
Managing Director
Co-Head of Healthcare Investment Banking
(646) 358-1901


James Antonopoulos
Managing Director
Co-Head of Healthcare Investment Banking
(646) 358-1906


Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703


Nazan Akdeniz
Senior Vice President
(949) 720-5740


Lou Ellis
Senior Vice President
(949) 720-5739

Transaction Information

Neovacs (Euronext Growth Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, has completed a €6.0 Million PIPE to U.S. Institutional Investors active in the biotechnology sector. Under the placement 9,230,769 ordinary shares were issued at €0.65 per share with attached equity warrants. The warrants will entitle their holders to purchase up to 7,846,154 additional ordinary shares at an exercise price of €1.00 per share. Neovacs plans to use the proceeds to finance the development plan of IFNα Kinoid, including:

  • Completion of international Phase IIb clinical trial in Lupus

  • Completion of Phase IIa clinical trial in Dermatomyositis (orphan disease)

  • Completion of preclinical proof of concept study in Type 1 Diabetes

ROTH Capital Partners acted as sole placement agent for the offering.

About Neovacs
Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNalpha Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology, allergies and Type 1 diabetes.The goal of the Kinoid approach is to enable patients to have access to safe and effective long-term treatments for these life-long diseases. For more information, please visit (Source: Company Press Release | 7/31/17)


About ROTH Capital Partners

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S.  For more information on ROTH, please visit

About ROTH Investment Banking Private Capital Institutional Sales & Trading
Research Corporate Services Marketing & Conferences Press Room

The material, information and  facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2017.